meRfi®-GM
PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
…
References (Sources)
- An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor
- Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
- Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
- Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy
- Parp Inhibitors for the Treatment of Ovarian Cancer
- Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysisMeta-Analysis
- Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease